Van Eck Associates Corp Alkermes Plc. Transaction History
Van Eck Associates Corp
- $78.1 Billion
- Q4 2024
A detailed history of Van Eck Associates Corp transactions in Alkermes Plc. stock. As of the latest transaction made, Van Eck Associates Corp holds 137,567 shares of ALKS stock, worth $4.86 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
137,567
Previous 104,986
31.03%
Holding current value
$4.86 Million
Previous $2.92 Million
35.29%
% of portfolio
0.01%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding ALKS
# of Institutions
375Shares Held
173MCall Options Held
231KPut Options Held
158K-
Black Rock Inc. New York, NY29.1MShares$1.03 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.5MShares$653 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD12.3MShares$433 Million0.04% of portfolio
-
State Street Corp Boston, MA8.81MShares$311 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY7.56MShares$267 Million3.55% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $5.8B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...